Chronic treatment with d-chiro-inositol prevents autonomic and somatic neuropathy in STZ-induced diabetic mice

Diabetes, Obesity and Metabolism

Volumn 13, Issue 3, 2011, Pages 243-250

  Farias, V X ^a   Macedo F H P ^a   Oquendo, M B ^a   Tome A R ^a   Bao S N ^b   Cintra, D O S ^b   Santos, C F ^a   Albuquerque, A A C ^a   Heimark, D B ^c   Larner, J ^c   Fonteles, M C ^a,d   Leal Cardoso, J H ^a   Nascimento, N R F ^a,e,f  

^a Superior Institute of Biomedical Sciences   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

^c UNIVERSITY OF VIRGINIA   (United States)

^d MACKENZIE PRESBYTERIAN UNIVERSITY   (Brazil)

^e STATE UNIVERSITY OF CEARÁ   (Brazil)

^f UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Autonomic neuropathy; Diabetic neuropathy; Experimental pharmacology; Inositols; Microvascular disease; Somatic neuropathy; Therapy of diabetic complications

Indexed keywords

INOSITOL; STREPTOZOCIN;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTONOMIC NEUROPATHY; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS CAVERNOSUM; ELECTRON MICROSCOPY; ELECTROSTIMULATION; ENDOTHELIAL DYSFUNCTION; MALE; MOUSE; NERVE INJURY; NEUROPROTECTION; NONHUMAN; RAT; SCIATIC NERVE; SOMATIC NEUROPATHY; STREPTOZOCIN DIABETES; TREATMENT RESPONSE; VAS DEFERENS;

EID: 78851471705     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01344.x     Document Type: Article

References (47)

1. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation: basis for prevention. Diabetes Care 1990; 13: 513-521.
2. Behse F, Buchthal F, Carlsen F. Nerve biopsy and conduction studies in diabetic neuropathy. J Neurol Neurosurg Psychiatry 1977; 40: 1072-1082.
3. Sima AAF, Nathaniel V, Bril V, Mcewen TAJ, Greene DA. Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axo-glial dysfunction in human diabetic neuropathy. J Clin Invest 1988; 81: 349-364.
4. Dick PJ, Giannini C. Pathologic alterations in the diabetic neuropathies of humans: a review. J Neuropathol 1996; 55: 1181-1193.
5. Vinik AI, Erbas T. Recognizing and treating diabetic autonomic neuropathy. Cleve Clin J Med 2001; 68: 928-944.
6. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003; 26: 1553-1579.
7. Cellek S, Rodrigo J, Lobos E, Fernandez P, Serrano J, Moncada S. Selective nitrergic neurodegeneration in diabetes mellitus: a nitric oxide-dependent phenomenon. Br J Pharmacol 1999; 128: 1804-1812.
8. Foss-Freitas MC, Marques Junior W, Foss MC. Autonomic neuropathy: a high risk complication for type 1 diabetes mellitus. Arq Bras Endocrinol Metabol 2008; 52: 398-406.
9. Cameron NE, Cotter MA, Harrison J. Effect of diabetes on motor conduction velocity in different branches of the rat sciatic nerve. Exp Neurol 1986; 92: 757-761.
10. Cameron NE, Cotter MA, Archibald V, Dines KC, Maxfield EK. Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats. Diabetologia 1994; 37: 449-459.
11. Greene DA, Steven MJ, Obrosova I, Feldman EL. Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy. Eur J Pharmacol 1999; 375: 217-223.
12. Vinik AI. Advances in diabetes for the millennium: new treatments for diabetic neuropathies. Med Gen Med 2004; 6(Suppl. 3): 13.
13. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820.
14. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625.
15. Feldman EL. Oxidative stress and diabetic neuropathy: a new understanding of an old problem. J Clin Invest 2003; 111: 431-433.
16. Nascimento NRF, Lessa LMA, Kerntopf MR et al. Inositols prevent and reverse endothelial dysfunction in diabetic rat and rabbit vasculature metabolically and scavenging superoxide. Proc Natl Acad Sci U S A 2006; 103: 218-223.
17. Cellek S, Rodrigo J, Lobos E, Fernández P, Serrano J, Moncada S. Selective nitrergic neurodegeneration in diabetes mellitus-a nitric oxide-dependent phenomenon. Br J Pharmacol 1999; 128: 1804-1812.
18. Cellek S, Foxwell NA, Moncada S. Two phases of nitrergic neuropathy in streptozotocin-induced diabetic rats. Diabetes 2003; 52: 2353-2362.
19. Gluck G, Anguelova T, Heimark D, Larner J. Synergistic effects of d-chiro-inositol and manganese on blood glucose and body weight of streptozotocin-induced diabetic rats. Curr Bioact Compd 2010; 6: 90-96.
20. Singh RK, Pandey BL, Tripathi M, Pandey VB. Anti-inflammatory effect of (+)-pinitol. Fitoterapia 2001; 72: 168-170.
21. Shin YC, Jeon JY. The physiological activities of pinitol isolated from soybean. Food Ind Nutr 2004; 9: 28-35.
22. Kim JC, Shin JY, Shin DH et al. Synergistic antiinflammatory effects of pinitol and glucosamine in rats. Phytother Res 2005; 19: 1048-1051.
23. Zhou Y, Park CM, Cho CW, Song YS. Protective effect of pinitol against d-galactosamine-induced hepatotoxicity in rats fed on a high-fat diet. Biosci Biotechnol Biochem 2008; 72: 1657-1666.
24. Sethi G, Ahn KS, Sung B, Aggarwal BB. Pinitol targets nuclear factor-kappaB activation pathway leading to inhibition of gene products associated with proliferation, apoptosis, invasion, and angiogenesis. Mol Cancer Ther 2008; 7: 1604-1614.
25. Sivakumar S, Subramanian SP. Pancreatic tissue protective nature of d-pinitol studied in streptozotocin-mediated oxidative stress in experimental diabetic rats. Eur J Pharmacol 2009; 622: 65-70.
26. Aidley DJ. The Physiology of Excitable Cells, 4th edn. Cambridge: Cambridge University Press, 1998; 35-71.
27. Holsheimer JD, Dijkstra EA, Demeulemeester H, Nutim B. Chronaxie calculated from current-duration and voltage-duration data. J Neurosci Methods 2000; 97: 47-50.
28. Leal-Cardoso JH, Moreira MR, Cruz GM, Morais SM, Lahlou MS, Coelho-de-Souza AN. Effects of the essential oil of Alpinia zerumbet on the compound action potential of the rat sciatic nerve. Phytomedicine 2004; 11: 549-553.
29. Greene DA, De Jesus PV Jr, Winegrad AI. Effects of insulin and dietary myoinositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin diabetes. J Clin Invest 1975; 55: 1326-1336.
30. Mayer JH, Tomlinson DR. Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats. Diabetologia 1983; 25: 433-438.
31. (+)-ATPase activity in isolated membrane fraction from sciatic nerves of streptozotocin-induced diabetic rats by dietary myo-inositol supplementation in vivo or protein kinase C agonists in vitro. Diabetes 1991; 40: 558-567.
32. Carrington AL, Calcutt NA, Ettlinger CB, Gustafsson T, Tomlinson DR. Effects of treatment with myo-inositol or its 1, 2, 6-trisphosphate (PP56) on nerve conduction in streptozotocin-diabetes. Eur J Pharmacol 1993; 237: 257-263.
33. (+)-ATPase activity in rats maintained on l-fucose diet. Reversal by myo-inositol supplementation. Diabetes 1993; 42: 1401-1406.
34. Sima AA, Dunlap JA, Davidson EP et al. Supplemental myo-inositol prevents l-fucose-induced diabetic neuropathy. Diabetes 1997; 46: 301-306.
35. Monckton G, Marusyk H. The effects of myoinositol on the autonomic neuropathy in the streptozotocin diabetic rat: a freeze fracture study. Can J Neurol Sci 1988; 15: 147-151.
36. Greene DA, Lattimer SA, Carroll PB, Fernstrom JD, Finegold DN. A defect in sodium-dependent amino acid uptake in diabetic rabbit peripheral nerve. Correction by an aldose reductase inhibitor or myo-inositol administration. J Clin Invest 1990; 85: 1657-1665.
37. Salway JG, Whitehead L, Finnegan JA, Karunanayaka A, Barnett D, Payne RB. Effect of myo-inositol on peripheral-nerve function in diabetes. Lancet 1978; 2: 1282-1284.
38. Chau JF, Lee MK, Law JW, Chung SK, Chung SS. Sodium/myo-inositol cotransporter-1 is essential for the development and function of the peripheral nerves. FASEB J 2005; 19: 1887-1889.
39. +/myo-inositol cotransporter. J Biol Chem 2002; 277: 35219-35224.
40. Lin X, Ma L, Fitzgerald RL, Ostlund RE Jr. Human sodium/inositol cotransporter 2 (SMIT2) transports inositols but not glucose in L6 cells. Arch Biochem Biophys 2009; 481: 197-201.
41. Fonteles MC, Almeida MQ, Larner J. Antihyperglycemic effects of 3-O-methyl-d-chiro-inositol and d-chiro-inositol associated with manganese in streptozotocin diabetic rats. Horm Metab Res 2000; 32: 129-132.
42. 3H]chiroinositol in rat tissues. J Biol Chem 1992; 267: 16904-16910.
43. Sun TH, Heimark DB, Nguygen T, Nadler JL, Larner J. Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Biophys Res Commun 2002; 293: 1092-1098.
44. Saenz De Tejada I, Goldstein I, Azadzoi KM, Krane RJ, Cohen RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. New Engl J 1989; 320: 1025.
45. Azadzoi KM, Saenz De Tejada I. Diabetes mellitus impairs neurogenic and endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle. J Urol 1992; 148: 1587-1591.
46. Agostini R, Rossi F, Pajalich R. Myoinositol/folic acid combination for the treatment of erectile dysfunction in type 2 diabetes men: a double-blind, randomized, placebo-controlled study. Eur Rev Med Pharmacol Sci 2006; 10: 247-250.
47. Güneş A, Ceylan A, Sarioglu Y, Stefek M, Bauer V, Karasu C. Antioxidants in diabetes-induced complications (ADIC) study group. Reactive oxygen species mediate abnormal contractile response to sympathetic nerve stimulation and noradrenaline in the vas deferens of chronically diabetic rats: effects of in vivo treatment with antioxidants. Fundam Clin Pharmacol 2005; 19: 73-79.